Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients
About one in five heart recipients with csCMVi developed post-treatment recurrence. A preceding episode of CMV disease and seroconversion was protective against recurrence. Lymphopenia may be a practical biomarker to stratify recurrence risk. Overall, recurrent csCMVi was not significantly associated with mortality.
Authors
- Raymund Rabe Razonable (ORCID: https://orcid.org/0000-0001-5248-0227)
- Zachary A. Yetmar (ORCID: https://orcid.org/0000-0003-2098-2868)
- Bismarck Bisono (ORCID: https://orcid.org/0000-0003-4329-4515)
- Elena Beam (ORCID: https://orcid.org/0000-0002-5807-2299)
- Holenarasipur R. Vikram (ORCID: https://orcid.org/0000-0002-6391-0349)
- Vaisak Nair (ORCID: https://orcid.org/0009-0006-7248-9222)
- Lisa Brumble (ORCID: https://orcid.org/0000-0001-5761-7309)
Institutions
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Jacksonville College (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1111/ctr.70342
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00